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Introduction
Preeclampsia is a pregnancy-specific condition characterized by decreased placental perfusion, new-onset hypertension, intrauterine growth restriction, and endothelial dysfunction. Affecting up to 10% of pregnancies in the United States, preeclampsia and hypertensive disorders of pregnancy are a leading cause of maternal and perinatal morbidity and mortality with few effective treatment options (Ananth et al., 2013; Roberts, 2013) . The complement system, part of the innate immune response, is an enzymatic amplification system composed of plasma proteins essential for host defense and inflammation. The complement system can be activated by multiple pathways with a central event being formation of the enzyme C3 convertase that cleaves C3 to generate fluid phase C3a as well as C3b that covalently binds to an invader or self, i.e. C3 deposition ( Figure 1 ). C3b serves as a nucleus for formation of C5 convertase that cleaves C5 into two fragments: C5a and the larger fragment C5b that inserts into membranes. Continuation of the cascade results in formation of membrane attack complex C5b-9 that either forms a pore in the membrane or is released as a soluble complex into circulation. Complement activation products include C3a, C5a and C5b-9. While the complement system is essential for fetal survival (Usami et al., 2010) and normal placental development (Singh et al., 2011) , excessive complement activation is associated with recurrent miscarriages, preterm labor and preeclampsia (Lynch and Salmon, 2010 studies were the first to describe a link between complement system activation and the hypertension resulting from third trimester placental ischemia in pregnancy (Lillegard et al., 2013) . We also demonstrated that angiogenic imbalance as well as impaired endothelialdependent relaxation in isolated blood vessels occurs in this model (Gilbert et al., 2010) .
Inhibiting complement activation attenuated hypertension in the RUPP model, but angiogenic imbalance, i.e. decreased vascular endothelial growth factor (VEGF), was still evident, suggesting that the role of complement in placental ischemia-induced hypertension was independent of VEGF. Complement activation products C3a and C5a are potent ~10kDa fluid phase inflammatory mediators that interact with G protein coupled receptors on many cell types to elicit biological activities including smooth muscle contraction and changes in blood pressure (Regal et al., 1980; Regal, 1982; Proctor et al., 2009) , activation and chemotaxis of immune cells, and increased vascular permeability (Klos et al., 2013) . In addition, excessive complement activation can adversely affect endothelial function (Collard et al., 2000) . With the realization of the importance of immune inflammatory pathways in numerous disease states, C3a and C5a receptor antagonists are being developed for potential clinical use and have also been used in numerous animal models to investigate the role of C3a and C5a in disease models (Ricklin and Lambris, 2013) . Using antagonists of the C3a and C5a receptor, the present study is the first to JPET #218123 6 test the hypothesis that C3a and C5a are the complement activation products that mediate endothelial dysfunction and hypertension following placental ischemia.
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Reduced utero-placental perfusion pressure (RUPP) procedure and antagonist administration RUPP procedure was performed on gestational day 14 (GD14) to achieve chronic placental ischemia and hypertension in pregnant rat on GD19 (See supplemental material for details) (Lillegard et al., 2013 
Complement measurements
C3a serum concentration was measured by Western immunoblot as described previously (Lillegard et al., 2013) and is expressed as C3a units/µl relative to the signal intensity of 1 µl of standard pool of yeast activated rat serum. Total complement hemolytic activity was measured as previously described and expressed as inverse dilution of serum causing 50% hemolysis of sensitized sheep erythrocytes (CH 50 ) (Lillegard et al., 2013) . The ability of C3aRA or C5aRA to inhibit complement activation in vitro was also assessed by incubation of antagonist or Veh with a pool of non-pregnant rat serum prior to determination of CH 50 .
Mesenteric artery myography
Third order mesenteric arteries were cleaned of adipose tissue and 2 mm segments mounted on 40 µm thick wires for myography as previously described (Gilbert et al., 2012a) . Buffers and vessel normalization were performed according to DMT Multi Wire Myography System User Manual (Model 610M, Danish Myo Technology, Aarhus, Denmark). Vessels were normalized to mimic a transmural pressure of 100 mm Hg and equilibrated 30-60 min with 3-4 buffer washes.
Diameters ranged from 200-350 µm, and vessels were pre-contracted with thromboxane-mimetic U46619 (5.7 X 10 -7 mol/L) followed by half log increments of acetylcholine (Ach; 0.03 to 33 X 10 -6 mol/L) to assess endothelial-dependent relaxation. After washing, vessels were contracted again with U46619 and relaxation to increasing concentrations of sodium nitroprusside (SNP; 0.01 to 333 X 10 -6 mol/L) was measured as an indicator of endothelial-independent vasodilation.
Finally, a cumulative concentration response curve to U46619 confirmed vessel reactivity.
Statistical analyses
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Results
Receptor antagonists attenuate placental ischemia-induced hypertension
To determine if complement activation products C3a and/or C5a were important in mediating placental ischemia-induced hypertension, we evaluated the effect of treatment with C3aRA or
C5aRA. Chronic placental ischemia caused a significant increase in MAP by GD19 ( Figure 2A ).
Clearly, treatment with either C3aRA or C5aRA significantly inhibited RUPP-induced increase in MAP without altering MAP in Sham animals. Treatment of animals with a combination of C3aRA and C5aRA did not result in greater attenuation of MAP than treatment with either antagonist alone (104±3 mm Hg, n=9; data not shown). As seen in Figure 2B , heart rate in RUPP rats was increased as previously described (Gilbert et al., 2012e) and was significantly decreased by treatment with C5aRA (p<0.05) but not C3aRA (p=0.11).
Placental ischemia-induced decrease in free plasma VEGF, fetal weight and resorptions is unaffected by receptor antagonists
As previously shown, placental ischemia resulted in decreased free plasma VEGF ( Figure C5aRA or in combination did not change the number of resorptions ( Figure S1 ).
C3aRA but not C5aRA inhibits increased C3a in vivo following placental ischemia
Relative serum C3a concentrations were used as an indicator of complement activation. Rat C5a
was not detectable by current assay methods. C3aRA and C5aRA were not expected to inhibit complement activation, but only antagonize actions of cleavage fragments C3a and C5a at their incubating the C3aRA (≤ 390 µg/ml) or C5aRA (≤100 µg/ml) with normal rat serum did not inhibit the CH 50 of the serum (data not shown) indicating that the antagonists were not altering classical hemolytic complement pathway activity in vitro.
C3aRA inhibits C3a-induced pressor response
Previous studies of others indicated differential vascular reactivity in pregnant vs non-pregnant rats (Paller, 1987) . Thus, the ability of C3a to cause a pressor response in the pregnant rat was
evaluated. An iv injection of 30 µg/kg C3a peptide in anesthetized pregnant dams on GD19 resulted in a rapid transient pressor response within minutes ( Figure 5 ), similar to the response in non-pregnant rats of a comparable age and size. Injection of the C3aRA (100 μ g/kg) itself did not significantly alter MAP in non-pregnant or pregnant rats at GD19 ( Figure 5 ), but it significantly inhibited the pressor response to 30 µg/kg C3a peptide in both non-pregnant and pregnant rats.
C5aRA reduces circulating neutrophils
Since studies of Proctor et al (Proctor et al., 2004) indicated that C3aRA exhibits partial agonist activity and affects circulating neutrophils in the non-pregnant rat, we determined the effect of RUPP model (LaMarca et al., 2013) . However, our studies were not designed to detect changes in lymphocyte subpopulations. Analysis of neutrophils in the lung demonstrated that neutrophils were not being sequestered in the lung by any of the treatments ( Figure S3 ).
C5aRA but not C3aRA attenuates endothelial dysfunction following placental ischemia
As previously demonstrated in this model, vasodilation in response to Ach was attenuated in mesenteric arteries from rats with placental ischemia (Figure 7) . In contrast, endothelialindependent vasodilation in response to SNP was not affected by placental ischemia ( Figure S4 ).
The C5aRA, but not the C3aRA, preserved endothelial function following placental ischemia as indicated by Ach-induced vasodilation equivalent to that seen in rats undergoing Sham Veh treatment. Combination treatment with both C3aRA and C5aRA affected Ach and SNP relaxation in the same way as C5aRA alone (data not shown). Both C3a and C5a have been reported to contract isolated blood vessels (Regal, 1982; Bjork et al., 1985) including microvessels in the hamster cheek pouch (Bjork et al., 1985) , but neither C3a peptide nor recombinant human C5a contracted the isolated rat mesenteric arteries (data not shown). In addition, neither C3aRA nor C5aRA significantly relaxed isolated mesenteric arteries whether at normal resting tension or when pre-contracted with the thromboxane mimetic U46619.
This article has not been copyedited and formatted. The final version may differ from this version. are the first to demonstrate both C3a and C5a contribute to placental ischemia-induced hypertension, and inhibiting both receptors was no more effective than inhibiting each receptor alone.
By design, multiple inflammatory mediators can be evoked by any given perturbation, thus promoting survival of the organism but also contributing to difficulty in treating inflammatory disease. If the action or synthesis of one mediator (i.e., C3a, C5a) is prevented, another mediator may assume a primary role in uncontrolled inflammation. Our studies, and those of others, suggest that increased inflammation in preeclampsia involves cytokines, T cells, autoantibodies and complement along with pro-and anti-angiogenic factors (LaMarca et al., 2013) . This complex interplay of mediators suggests that therapy of pregnancy-induced hypertension will be a challenge similar to treatment of general inflammatory disease. Both endothelial dysfunction and increased heart rate may contribute to cardiovascular abnormalities observed in preeclampsia and the RUPP rat model (Gilbert et al., 2012e) . The
C5aRA prevented endothelial dysfunction and increased heart rate associated with RUPP hypertension suggesting that C5a substantially contributes to both in the RUPP model. We have previously shown that C5a has positive chronotropic effects on isolated male guinea pig atria (Regal, 1985) . Thus, it is possible that C5aRA prevents a direct action of C5a on cardiomyocytes to increase heart rate in the RUPP. Alternatively, C5aRA treatment may decrease sympathetic tone reportedly elevated in RUPP rat (Hines et al., 2007) . However, the relevance of this to cardiovascular function in preeclampsia remains unclear (Greenwood et al., 2001 ). C5aRA also decreased circulating neutrophils in our study consistent with recent data indicating C5a stimulates production of granulocyte colony stimulating factor (Bosmann et al., 2013) , a substance known to play a role in regulating number of neutrophils in circulation. C5a
is also a potent neutrophil activator. The difficulty in detecting increases in C5a in circulation may be due to binding of any C5a generated in the circulation to the very high affinity receptor for C5a on neutrophils. However, our data demonstrate no evidence that the RUPP procedure, nor the C3aRA or C5aRA result in neutrophil activation with resultant pulmonary sequestration.
Our preliminary studies indicate that depletion of neutrophils also attenuates placental ischemiainduced hypertension (Lillegard KE, 2013) suggesting that C5aRA could be limiting placental ischemia-induced hypertension by a neutrophil-dependent effect.
Clearly a limitation of our study lies in inherent limitations of receptor antagonists.
PMX53, the C5aRA chosen for this study, has been used in numerous animal models in both mice and rats to assess the importance of C5a in mediating a response through the C5a receptor (CD88; C5aR; C5aR1). It is important to recognize that C5a can interact with another receptor (C5L2; C5aR2), but PMX53 does not alter C5a action at this second C5a receptor (Klos et al., 2013) . Both the C5aR and C5L2 mediate production of granulocyte colony stimulating factor (G-CSF) by C5a (Bosmann et al., 2013) , and C5aR and C5L2 can form heteromers to regulate C5a function with heteromer formation being inhibited by C5aRA (Croker et al., 2013) . Our studies do not provide information regarding the importance of C5L2 or the cell or tissue location of the important C5aR for mediating hypertension. Further studies are needed to investigate these possibilities.
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Both C3a and C5a have distinct acute hemodynamic effects in the anesthetized rat, with
C3a increasing blood pressure transiently and C5a causing a more prolonged decrease in blood pressure (Proctor et al., 2009 ). In the guinea pig, we previously demonstrated that C5a increases blood pressure via thromboxane, and the acute increase in blood pressure is dependent on white blood cells and platelets (Fraser and Regal, 1990) . Vascular reactivity to agonists can vary during pregnancy when compared to the non-pregnant state (Paller, 1987) , but our current studies indicate that a pregnant rat reacts to C3a peptide with a similar acute pressor response as a non-pregnant rat (Proctor et al., 2006) . C3aRA prevents the increase in blood pressure indicating that it is an effective C3aR antagonist in the pregnant and non-pregnant rat. The reduction in circulating C3a following administration of the C3aRA SB290157 suggests that it has other effects and may exert its inhibitory effect on placental ischemia-induced hypertension by non-C3aR actions such as interfering with generation of C3a or complement activation in general. SB290157 in vitro has demonstrated high efficacy and specificity for the C3a receptor in rat and human cells and does not disrupt C5a-mediated cellular responses in vitro (Ames et al., 2001 ). However, Proctor et al noted that SB290157 in vivo caused an acute transient increase in blood pressure and decrease in circulating neutrophils with iv injection suggesting it was also acting as a C3a receptor agonist (Proctor et al., 2004) . They concluded that the favorable effect of SB290157 in intestinal ischemia/reperfusion was likely due to its agonist action on neutrophils rather than its antagonism of C3aR (Wu et al., 2013) . Mathieu et al (Mathieu et al., 2005 ) also described agonist activity of SB290157 in systems with high C3aR density, and others observed similar agonist properties in Chinese hamster ovary cells and human U937 cells (Scully et al., 2010) . In our study, the most perplexing limitation of C3aRA was the fact that at 5 mg/kg it inhibited the RUPP-induced increase in C3a itself and an explanation for this is not readily apparent. These data temper conclusions regarding the importance of C3a in our studies and suggest that the C3aRA is affecting hypertension by both C3a receptor and non-receptor pathways. In addition, our studies temper a conclusive role for C3aR in hypertension and proteinuria in pregnancy following adoptive transfer of AT1-AA into third trimester mice (Wang et al., 2012) where doses up to 30 mg/kg/day SB290157 were used to provide evidence for an important role of C3a. In our studies, the C3aRA SB290157 definitely inhibits increases in blood pressure following either C3a administration or placental ischemia suggesting that C3a is an important mediator of placental ischemia-induced hypertension. However, non-C3aR effects of SB290157 may also be operating in vivo to reduce placental ischemia-induced hypertension.
In a recently published case report by Burwick et al , eculizumab, an antibody to C5, favorably extended pregnancy in a woman with severe preeclampsia. Whether eculizumab was effective in prolonging pregnancy because of its ability to limit C5a or C5b-9 formation or both is unknown. However, our studies in the rat model suggest that eculizumab may attenuate the severity of preeclampsia in part through its ability to limit formation of C5a and further studies are underway to evaluate this possibility. Our studies to date have also not addressed how complement is activated following placental ischemia or which pathway(s) of complement activation is leading to the increase in circulating C3a. In a pregnant mouse model, studies of Wang et al (Wang et al., 2012) indicate that infusion of autoantibodies to the angiotensin II Type 1 receptor lead to complement activation and hypertension so a role for autoantibodies in RUPP-induced complement activation is possible. In addition, future immunohistochemistry studies are warranted to determine the site of complement activation by determining if C3 deposition is occurring in the vasculature and/or placenta and is associated with the increased blood pressure seen following placental ischemia.
Measurement of neutrophils in the lung
To determine if the decreased number of circulating neutrophils was due to their sequestration in the lung, lung lobes were removed on GD19 and processed as previously described for determination of myeloperoxidase content as an indicator of the number of neutrophils in the tissue at necropsy (Fraser et al., 1995) . Protein content was determined using the DC Protein assay method (BioRad, Hercules, CA). Myeloperoxidase was expressed as Units MPO activity per mg protein in supernatants of detergent extracted cell homogenate. 
